Phentermine

From Wikipedia, the free encyclopedia

Jump to: navigation, search
Phentermine
Systematic (IUPAC) name
2-methyl-1-phenylpropan-2-amine and 2-methyl-amphetamine
Identifiers
Chemical data
Formula C10H15N 
Mol. mass 149.233 g/mol
Pharmacokinetic data
Bioavailability Peak plasma levels occur within 1 to 4.5 hours. Absorption is usually complete by 4 to 6 hours
Protein binding Approximately 96.3%
Metabolism hepatic
Half life 16 to 31 hours
Excretion Urinary elimination
Therapeutic considerations
Routes Oral

Phentermine, a contraction for "phenyl-tertiary-butylamine", is an appetite suppressant of the amphetamine and phenethylamine class.

It is approved as an appetite suppressant to help reduce weight in obese patients when used short-term and combined with exercise, diet, and behavioral modification. It is typically prescribed for individuals who are at increased medical risk because of their weight and works by helping to release certain chemicals in the brain that control appetite.

[edit] Commercial trade names

Adipex P (Immediate release) Avaprex (Non Rx Immediate release) Anoxine-AM Fastin (discontinued) Ionamin (Slow Release Resin, Australia, discontinued in the US) Duromine (Slow Release Resin, New Zealand & Australia) Mirapront Obephen Obermine Obestin-30 Phentrol Phenterex Phentromin Pro-Fast SA Redusa Panbesy Phentermine Trenker Obenix Oby-Trim Teramine Zantryl Sinpet (MX) Supremin (PH) Umine (NZ) Weltmine (KP)

[edit] History

In 1959 phentermine first received approval from the FDA as an appetite suppressing drug. Phentermine hydrochloride then became available in the early 1970s. It was previously sold as Fastin from King Pharmaceuticals for SmithKline Beecham, however in 1998 it was removed from the market. Medeva Pharmaceuticals sells the name brand of phentermine called Ionamin and Gate Pharmaceuticals sells it as Adipex-P. Phentermine is also currently sold as a generic. Since the drug was approved in 1959 there have been almost no clinical studies performed. The most recent study was in 1990 which combined phentermine with fenfluramine or dexfenfluramine and became known as Fen-Phen.[citation needed]

A study was published in 1992 that Fen-Phen was more effective than diet and exercise with few side effects.[citation needed] However, in 1997 after 24 cases of heart valve disease in Fen-Phen users, fenfluramine and dexfenfluramine were voluntarily taken off the market at the request of the FDA. Studies later proved that nearly 30% of people taking fenfluramine or dexfenfluramine had abnormal valve findings. The FDA did not ask manufacturers to remove phentermine from the market.

Phentermine is still available by itself in most countries, including the U.S. However, because it is similar to amphetamines, individuals may develop an addiction to it. Hence, it is classified as a controlled substance in many countries. Internationally, phentermine is a schedule IV drug under the Convention on Psychotropic Substances.[1] In the United States, it is classified as a Schedule IV controlled substance under the Controlled Substances Act.

[edit] Mechanism of action

Phentermine, like many other prescription drugs, works with neurotransmitters in the brain. It is a centrally-acting stimulant and is a constitutional isomer (not to be confused with stereoisomer) of methamphetamine. It stimulates neuron bundles to release a particular group of neurotransmitters known as catecholamines; these include dopamine, epinephrine (also known as adrenaline), and norepinephrine (noradrenaline). The anorectic activity seen with these compounds is thus likely due to their effect on the central nervous system, which is consistent with current knowledge about the central nervous system and feeding behavior. This is the same mechanism of action as other stimulant appetite suppressants such as diethylpropion and phendimetrazine. The neurotransmitters signal a fight-or-flight response in the body which, in turn, puts a halt to the hunger signal. As a result, it causes a loss in appetite because the brain does not receive the hunger message.[citation needed]

[edit] Dosing and administration

Generally, it is recommended by the Food and Drug Administration (FDA) that phentermine should be used short-term (usually interpreted as 'up to 12 weeks'), while following nonpharmacological approaches to weight loss such as healthy dieting and exercise.[citation needed]

[edit] Contraindications and warnings

Patients with the following should not use Phentermine:
An allergy to any ingredient in Phentermine or other sympathomimetics (eg, pseudoephedrine) Are also taking dexfenfluramine, fenfluramine, furazolidone, guanadrel, guanethidine, or have taken a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) in the last 14 days Have severe high blood pressure, an overactive thyroid, glaucoma, heart or blood vessel disease, or severe narrowing of the blood vessels Are in an agitated state, or have a history of substance abuse
Some medical conditions may interact with Phentermine, patients with the following should consult with their doctor before using phentermine:
Are pregnant, planning to become pregnant, or are breast-feeding Are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement Have allergies to medicines, foods, or other substances Have a brain or spinal cord disorder, hardening of the arteries, high blood pressure, diabetes, or high cholesterol or lipid levels
Some medicines may interact with phentermine, such as the following:
Dexfenfluramine, fenfluramine, furazolidone, or MAOIs (eg, phenelzine) because the risk of serious side effects, such as increasing headache, high blood pressure, slow heart rate, elevated temperature, or possibly fatal lung problems, may be increased Serotonin specific reuptake inhibitors (citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), fluvoxamine (Luvox), paroxetine (Paxil), or sertraline (Zoloft)) because the risk of their side effects may be increased by Phentermine Guanadrel(Hylorel) or guanethidine(Ismelin) because their effectiveness may be decreased by phentermine Antacids: Antacids may decrease the excretion of phentermine. [2] Carbonic anhydrase inhibitors (acetazolamide, dichlorphenamide, methazolamide): Carbonic anhydrase inhibitors may decrease the excretion of phentermine.[2]

[edit] Side effects

Generally, phentermine appears to be relatively well tolerated.[3] It can produce side effects consistent with its catecholamine-releasing properties, e.g., tachycardia (increased heart rate) and elevated blood pressure, but the incidence and magnitude of these appear to be less than with the amphetamines. Because phentermine acts through sympathomimetic pathways, the drug may increase blood pressure and heart rate. It may also cause palpitations, restlessness, and insomnia. Additionally, phentermine has the potential to cause physical and psychological dependence.

[edit] More common symptoms

Insomnia Increased blood pressure Irritability Nervousness Sense of well-being Dry mouth Unpleasant taste Blurred vision Heartburn/Acid reflux Change in sexual desire Clumsiness Confusion Diarrhea Dizziness Headache Irregular heartbeat Nausea or vomiting Psychosis Skin rash or itching Stomach pain Tiredness

[edit] Less common symptoms

Convulsions (seizures) Dizziness Fever Hallucinations Hostility with urge to attack Irregular blood pressure Lightheadedness or fainting Mental depression, following a period of excitement Tremors, trembling or shaking Overactive reflexes Panic Restlessness Severe nausea, vomiting or diarrhea Stomach cramps Tiredness or weakness

[edit] References

^ Incb.org (PDF file) ^ a b "Phentermine". Merck & Co., Inc. (2008). Retrieved on 2008-05-15. ^ Nelson DL, Gehlert DR. (2006). "Central nervous system biogenic amine targets for control of appetite and energy expenditure." (HTML). Endocrine. 2006 Feb;29(1):49-60. PubMed. Retrieved on 6 May 2006.

[edit] External links


You are viewing a mobilized version of this site...
View original page here

Mobilized by Mowser Mowser